Table 1 Clinical and molecular features of the patients used for the analysis of EPZ005687 in primary patient CD138 selected cells

From: Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Patient number

Clinical features

Molecular features

 

Age at the time of relapse (years)

No. of prior therapies

Time from first diagnosis (months)

Previously exposed to:

Translocation group/HRD

Copy number changes associated with risk

    

IMiD

PI

  

1

57

2

36

Y

Y

None

17p−

2

56

1

27

Y

Y

t(11;14)

None

3

69

6

109

Y

Y

t(4;14) FGFR3-

1p−, 1q amp

4

50

4

33

Y

Y

t(4;14) FGFR3+

1q+

5

66

2

40

Y

Y

None

1q+

6

85

1

46

Y

N

HRD

1q+, 17p−

Median

61.5

2

38

    
  1. Abbreviations: HRD, hyperdiploid; IMiD, immunomodulatory drug; N, no; PI, proteasome inhibitor; Y, yes.
Back to article page